These are the stocks posting the largest moves before the bell.Market Insiderread more
The Fed is expected to cut rates Wednesday, but it is unlikely to tell markets what they want to hear on future rate cuts.Market Insiderread more
Corporate executives and money managers have grown increasingly pessimistic about the economy as growth around the world slows.Trader Talk with Bob Pisaniread more
Facebook unveils the Portal TV, a streaming device that comes with a camera and microphones for making video calls via television.Technologyread more
U.S. homebuilding surged to more than a 12-year high in August as both single- and multi-family housing construction increased.Economyread more
Four Wall Street firms downgraded FedEx after the company's poor earnings report.Marketsread more
FedEx says trade around the world is starting to feel the squeeze of increased tariffs.Marketsread more
U.S. stock futures point to a modestly lower Wednesday morning open on Wall Street ahead of what the markets in the afternoon expect to be the Fed's second interest rate cut...Marketsread more
Mortgage applications to purchase a home increased 6% for the week and were a strong 15% higher annually.Real Estateread more
The House subcommittee that oversees consumer product investigations launched its a probe of Juul in June, holding two days of hearings in July. In a letter to Juul sent...Health and Scienceread more
Pelosi said Trump should not have tried to address China's trade practices in a way that opened Americans up to financial pain.Politicsread more
Drug distributor Cardinal Health warned on Tuesday that its business could be hurt as it defends itself against several opioid-related lawsuits.
Several pharmaceutical wholesale distributors, including Cardinal, have been named as defendants in about 2,500 lawsuits for the distribution of prescription opioid pain medications. These lawsuits have been filed in various federal, state, and other courts by a variety of plaintiffs.
Cardinal said in a filing it expects to be named as a defendant in additional lawsuits.
Pharmaceutical manufacturers and distributors have been in part blamed for the U.S. opioid crisis, accused of deceptively marketing opioids in ways that downplayed their risks.
Cardinal said it was vigorously defending itself in all opioid-related matters, but is unable to predict their outcome or estimate a range of reasonably possible losses.
Cardinal said that ongoing negative publicity could hurt the its reputation or results of operations.
Opioids were involved in 400,000 overdose deaths from 1999 to 2017, according to the U.S. Centers for Disease Control and Prevention.
Earlier this month, Bloomberg News reported that McKesson, Cardinal Health, and AmerisourceBergen had proposed paying a $10 billion settlement for claims that they played a part in the U.S. opioid epidemic.